These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9013289)

  • 1. Improved CEDIA benzodiazepine assay eliminates sertraline crossreactivity.
    Fitzgerald RL; Herold DA
    J Anal Toxicol; 1997; 21(1):32-5. PubMed ID: 9013289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the diagnostic performance of the Boehringer Mannheim CEDIA LSD assay.
    Verstraete AG; Steyaert S
    J Anal Toxicol; 1998; 22(7):601-4. PubMed ID: 9847012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of EMIT II, CEDIA, and DPC RIA assays for the detection of lysergic acid diethylamide in forensic urine samples.
    Wiegand RF; Klette KL; Stout PR; Gehlhausen JM
    J Anal Toxicol; 2002 Oct; 26(7):519-23. PubMed ID: 12423010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
    Darragh A; Snyder ML; Ptolemy AS; Melanson S
    Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values.
    Fraser AD; Meatherall R
    J Anal Toxicol; 1996; 20(4):217-23. PubMed ID: 8835658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty.
    Mina A
    J Pharmacol Toxicol Methods; 2020; 101():106649. PubMed ID: 31730939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine.
    Fraser AD; Howell P
    J Anal Toxicol; 1998; 22(1):50-4. PubMed ID: 9491969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitations of EMIT benzodiazepine immunoassay for monitoring compliance of patients with benzodiazepine therapy even after hydrolyzing glucuronide metabolites in urine to increase cross-reactivity: comparison of immunoassay results with LC-MS/MS values.
    Dixon RB; Floyd D; Dasgupta A
    Ther Drug Monit; 2015 Feb; 37(1):137-9. PubMed ID: 25004136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of assay methods for benzodiazepines in urine. A receptor assay, two immunoassays, and gas chromatography-mass spectrometry.
    Nishikawa T; Ohtani H; Herold DA; Fitzgerald RL
    Am J Clin Pathol; 1997 Mar; 107(3):345-52. PubMed ID: 9052386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between the CEDIA and EMIT II immunoassays for the determination of benzodiazepines.
    Way BA; Walton KG; Koenig JW; Eveland BJ; Scott MG
    Clin Chim Acta; 1998 Mar; 271(1):1-9. PubMed ID: 9564553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved cross-reactivity to alpha OH triazolam in the BMC CEDIA DAU urine benzodiazepine assay.
    Fraser AD; Meatherall R
    Ther Drug Monit; 1998 Jun; 20(3):331-4. PubMed ID: 9631932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study.
    Schwettmann L; Külpmann WR; Vidal C
    Clin Chem Lab Med; 2006; 44(4):479-87. PubMed ID: 16599844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
    Pettersson Bergstrand M; Helander A; Hansson T; Beck O
    Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of cloned enzyme donor immunoassay cut-offs for drugs of abuse in whole blood of drivers involved in road accidents.
    Pelletti G; Garagnani M; Rossi F; Roffi R; Barone R; Pelotti S
    Forensic Sci Int; 2019 Jan; 294():27-33. PubMed ID: 30447484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of drugs of abuse detection in meconium by EMIT II and ELISA.
    Marin SJ; Keith L; Merrell M; McMillin GA
    J Anal Toxicol; 2009 Apr; 33(3):148-54. PubMed ID: 19371463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved screening for benzodiazepine metabolites in urine using the Triage Panel for Drugs of Abuse.
    Koch TR; Raglin RL; Kirk S; Bruni JF
    J Anal Toxicol; 1994; 18(3):168-72. PubMed ID: 7914948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening.
    Armbruster DA; Hubster EC; Kaufman MS; Ramon MK
    Clin Chem; 1995 Jan; 41(1):92-8. PubMed ID: 7813088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New fluorescence polarization immunoassays for analysis of barbiturates and benzodiazepines in serum and urine: performance characteristics.
    Schwenzer KS; Pearlman R; Tsilimidos M; Salamone SJ; Cannon RC; Wong SH; Gock SB; Jentzen JJ
    J Anal Toxicol; 2000; 24(8):726-32. PubMed ID: 11110029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEDIA for screening drugs of abuse in urine and the effect of adulterants.
    Wu AH; Forte E; Casella G; Sun K; Hemphill G; Foery R; Schanzenbach H
    J Forensic Sci; 1995 Jul; 40(4):614-8. PubMed ID: 7595298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LSD screening in urine performed by CEDIA® LSD assay: positive interference with sertraline.
    Citterio-Quentin A; Seidel E; Ramuz L; Parant F; Moulsma M
    J Anal Toxicol; 2012 May; 36(4):289-90. PubMed ID: 22511703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.